Targeted Therapy in the Management of Modern Craniopharyngiomas.
BRAF
CTNNB1
EGFR
adamantinomatous
beta-catenin
craniopharyngioma
immunotherapy
molecular biology
papillary
Journal
Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996
Informations de publication
Date de publication:
20 04 2022
20 04 2022
Historique:
received:
29
11
2021
revised:
26
01
2022
accepted:
09
02
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
28
4
2022
Statut:
ppublish
Résumé
The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP. Genetic and immunological markers show variable expression in different types of CP. Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
Sections du résumé
BACKGROUND
The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment.
METHODS
We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP.
RESULTS
Genetic and immunological markers show variable expression in different types of CP.
CONCLUSIONS
Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
Identifiants
pubmed: 35468695
pii: S2768-6701(22)00477-4
doi: 10.31083/j.fbl2704136
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2022 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. JJE (Mizuho–royalties), MK (Thieme–royalties).